Welcome to our dedicated page for enGene Therapeutics news (Ticker: ENGN), a resource for investors and traders seeking the latest updates and insights on enGene Therapeutics stock.
enGene Therapeutics Inc. develops non-viral genetic medicines for delivery to mucosal tissues and other organs. The company’s lead program is detalimogene voraplasmid, also known as detalimogene, for non-muscle invasive bladder cancer. Detalimogene is being evaluated in the multi-cohort LEGEND Phase 2 trial, including a pivotal cohort in high-risk, Bacillus Calmette-Guérin-unresponsive patients with carcinoma in situ, with or without concomitant papillary disease.
Recurring enGene news includes LEGEND clinical data, FDA designation and manufacturing-readiness updates, business and financial results, debt and equity financing activity, investor-conference participation, and corporate matters such as the completed name change from enGene Holdings Inc. to enGene Therapeutics Inc. The company’s common shares trade on Nasdaq under ENGN, and its listed warrants trade under ENGNW.
enGene Holdings (NASDAQ: ENGN) has appointed Dr. Hussein Sweiti as Chief Medical Officer, effective September 29, 2025. Dr. Sweiti, a surgical oncologist with over 15 years of experience, joins from Johnson & Johnson where he was Global Medical Head of Oncology Clinical Development and played a key role in securing FDA approval for a bladder cancer treatment.
Dr. Sweiti will oversee enGene's global clinical development strategy for detalimogene, their lead candidate for non-muscle invasive bladder cancer (NMIBC). His appointment comes at a crucial time as enGene prepares for a planned BLA submission in the second half of 2026, following the completion of target enrollment in detalimogene's pivotal NMIBC clinical trial.
enGene Holdings (NASDAQ:ENGN) reported key milestones and financial results for Q3 2025. The company achieved target enrollment of 100 patients for the pivotal cohort of its LEGEND trial studying detalimogene in high-risk BCG-unresponsive NMIBC. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid, providing regulatory advantages including potential rolling submission and priority review.
Financial highlights include $224.9 million in cash and marketable securities, providing runway into 2027. Q3 operating expenses increased to $29.9 million, with a net loss of $0.57 per share. The company plans to provide LEGEND trial data updates in Q4 2025 and submit a BLA filing in 2H 2026.
enGene Holdings (NASDAQ:ENGN) has reached a significant milestone in its LEGEND Phase 2 trial for detalimogene voraplasmid, achieving the target enrollment of 100 patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS).
The company plans to overenroll in its pivotal cohort and has adjusted its timeline for Biologic License Application (BLA) submission to 2H 2026. An update from the LEGEND trial's pivotal cohort is expected in Q4 2025. The trial aims to develop the first non-viral gene therapy for NMIBC, focusing on balancing efficacy, safety, and ease of use.
enGene Holdings (Nasdaq: ENGN), a clinical-stage non-viral gene therapy company, has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Wells Fargo Healthcare Conference on September 3 at 8:45 a.m. ET, the H.C. Wainwright Global Investment Conference on September 8 at 1:30 p.m. ET, and the Morgan Stanley Global Healthcare Conference on September 10 at 1:50 p.m. ET.
All presentations will be available via webcast on the company's website under the "Investors" section and will remain accessible for 90 days following the events.
enGene Holdings (NASDAQ: ENGN), a clinical-stage non-viral gene-based immunotherapy company, has granted inducement equity awards to three new employees effective July 31, 2025. The awards include non-qualified stock options to purchase 93,200 common shares at an exercise price of $3.79 per share.
The stock options have a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over three years. These grants were approved by the independent Compensation Committee as employment inducements under NASDAQ Rule 5635(c)(4).
enGene Holdings (NASDAQ: ENGN) has announced significant leadership changes to support its commercial readiness, particularly for its lead therapy detalimogene. The company appointed three industry veterans to its Board of Directors: Philip Astley-Sparke, former BioVex CEO and Replimune co-founder; William Grossman, M.D., Ph.D., former Gilead Sciences SVP; and Michael Heffernan, Collegium Pharmaceutical founder.
Additionally, enGene made key management promotions: Matthew Boyd as Chief Regulatory Officer, Jill Buck as Chief Development Officer, and Katherine Chan, M.D., M.P.H. as Executive Director, Urology Clinical Lead. These appointments strengthen the company's clinical and regulatory operations as it prepares for planned regulatory filings and commercialization of its non-viral gene-based immunotherapy pipeline.
enGene (NASDAQ: ENGN) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for detalimogene voraplasmid, its lead therapy for high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC). The designation was based on promising preliminary results from the LEGEND study showing compelling clinical activity and favorable tolerability.
The RMAT designation provides significant regulatory advantages, including expedited development and review process, early FDA engagement, potential rolling review, and priority review benefits. Detalimogene is designed for efficient administration in urology clinics, targeting approximately 70% of urologists who provide care in community practices.